ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3009

Stem Cell Augmentation for Cardiovascular Risk in Rheumatoid Arthritis

Nidhi Garg1, Ashit Syngle2 and Pawan Krishan1, 1Deptt. of Pharmaceutical Sciences & Drug Research, Punjabi University Patiala, India, Patiala, India, 2Cardio Rheuma, Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: endothelial cells and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Bone marrow derived stem cells, endothelial progenitor cells (EPCs), protect against atherosclerotic vascular damage by overcoming endothelial damage. However, EPCs are depleted in RA and contribute to the enhanced cardiovascular (CV) risk. Therapeutic potential of augmenting EPCs to treat the heightened CV risk of RA has not yet been exploited. We aimed to investigate the effect of rosuvastatin on EPCs population, endothelial dysfunction, nitrite, adhesion molecules and on markers of inflammation in RA.

Methods:

50 RA patients were randomized to receive 24 weeks of treatment with rosuvastatin (10mg/day, n=25) or placebo (n=25) as an adjunct to existing stable antirheumatic drugs. EPCs (CD34+/CD133+) were quantified by Flow Cytometry. Flow mediated dilatation (FMD) was assessed by AngiodefenderTM (Everest Genomic Ann Arbor, United States). Inflammatory measures included DAS28, CRP, ESR and Pro-inflammatory cytokines (TNF-α, IL-6 and IL-1) were measured at baseline and after treatment. Estimation of serum nitrite, Lipids, and adhesion molecules (ICAM-1 and VCAM-1) was done at baseline and after treatment.

Results:

At baseline, inflammatory measures, pro-inflammatory cytokines, adhesion molecules and nitrite levels were elevated and EPCs and endothelial function were impaired among both groups. At 24 wks: DAS28, ESR, CRP, TNF-α and IL-6 improved significantly (p<0.05) in rosuvastatin group. Concentration of serum nitrite (p=0.02) and ICAM-1 (p=0.01) was significantly lower in the rosuvastatin group compared with placebo. EPCs increased significantly from (CD34+/CD133+, 0.01±0.001 to 0.035±0.001, p<0.01) after treatment with rosuvastatin as compared with placebo and after 24 wks percentage change in EPCs was 71.4% and 22.2% in the rosuvastatin and placebo groups respectively (Fig.1). After treatment with rosuvastatin there was significant improvement in FMD (p<0.01) as compared to placebo. Rosuvastatin exerted positive effect on lipid spectrum by signicantly increasing HDL cholesterol levels (p=0.01) and decreasing LDL cholesterol (p=0.02). Significant inverse correlation was observed between EPCs and CRP (r=-0.44, p=0.02), TNF-α (r=-0.42, p=0.03), ICAM-1(r=-0.45, p=0.03) and FMD(r=-0.47, p=0.01) after treatment with rosuvastatin.

 

Conclusion: First study to show that rosuvastatin augments EPCs population in RA mediated by lowering the levels of cytokines, especially IL-6 and TNF-α, which downregulates adhesion molecule, CRP and nitric oxide production. This defines a novel mechanism of rosuvastatin treatment in patients with RA: the augmentation of EPCs with improvement in inflammatory disease activity and endothelial dysfunction. The augmentation of EPCs by rosuvastatin represents a fascinating new approach for the management of RA.


Disclosure:

N. Garg,
None;

A. Syngle,
None;

P. Krishan,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stem-cell-augmentation-for-cardiovascular-risk-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences